[go: up one dir, main page]

MEP36508A - Triazolopyrazine derivatives useful as anti-cancer agents - Google Patents

Triazolopyrazine derivatives useful as anti-cancer agents

Info

Publication number
MEP36508A
MEP36508A MEP-365/08A MEP36508A MEP36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A ME P36508 A MEP36508 A ME P36508A
Authority
ME
Montenegro
Prior art keywords
cancer agents
derivatives useful
triazolopyrazine derivatives
compounds
formula
Prior art date
Application number
MEP-365/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Hengmiao Cheng
Jingrong Jean Cui
Jacqui Elizabeth Hoffman
Lei Jia
Mary Catherine Johnson
Robert Steven Kania
Phuong Thi Quy Le
Mitchell David Nambu
Mason Alan Pairish
Hong Shen
Michelle Bich Tran-Dube
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MEP36508A publication Critical patent/MEP36508A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-365/08A 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents MEP36508A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79996606P 2006-05-11 2006-05-11
US89323107P 2007-03-06 2007-03-06
PCT/IB2007/001142 WO2007132308A1 (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Publications (1)

Publication Number Publication Date
MEP36508A true MEP36508A (en) 2011-02-10

Family

ID=38441445

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-365/08A MEP36508A (en) 2006-05-11 2007-04-30 Triazolopyrazine derivatives useful as anti-cancer agents

Country Status (32)

Country Link
US (2) US7732604B2 (es)
EP (1) EP2018383B1 (es)
JP (1) JP4377962B2 (es)
KR (1) KR101099161B1 (es)
CN (1) CN101443331A (es)
AP (1) AP2008004674A0 (es)
AR (1) AR060994A1 (es)
AT (1) ATE532785T1 (es)
AU (1) AU2007251283A1 (es)
BR (1) BRPI0711809A2 (es)
CA (1) CA2651363C (es)
CR (1) CR10383A (es)
EA (1) EA016204B1 (es)
EC (1) ECSP088871A (es)
ES (1) ES2376913T3 (es)
GE (1) GEP20115174B (es)
GT (1) GT200700039A (es)
HN (1) HN2007015177A (es)
IL (1) IL194813A0 (es)
MA (1) MA30411B1 (es)
ME (1) MEP36508A (es)
MX (1) MX2008014399A (es)
NL (1) NL2000613C2 (es)
NO (1) NO20085060L (es)
NZ (1) NZ572361A (es)
PE (1) PE20080067A1 (es)
RS (1) RS20080533A (es)
TN (1) TNSN08445A1 (es)
TW (1) TWI346115B (es)
UY (1) UY30334A1 (es)
WO (1) WO2007132308A1 (es)
ZA (1) ZA200809020B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8198448B2 (en) * 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
US20110039856A1 (en) * 2007-11-29 2011-02-17 Pfizer Inc. Polymorphs of a c-met/hgfr inhibitor
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
CA2716898A1 (en) * 2008-02-27 2009-09-03 Takeda Pharmaceutical Company Limited Compound having 6-membered aromatic ring
CA2717034A1 (en) * 2008-02-28 2009-09-03 Pascal Furet Imidazo[1,2-b]pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease
AU2009222122A1 (en) * 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
JPWO2009157196A1 (ja) * 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
US8912330B2 (en) 2008-12-12 2014-12-16 Ariad Pharmaceuticals, Inc. Azaindole derivatives as kinase inhibitors
WO2010072295A1 (en) 2008-12-22 2010-07-01 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
CN102459283B (zh) * 2009-05-28 2014-11-12 沃泰克斯药物股份有限公司 C-met 蛋白激酶的氨基吡唑三唑并噻二唑抑制剂
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
DE102009056886A1 (de) * 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
WO2011079804A1 (en) * 2009-12-31 2011-07-07 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
TWI423974B (zh) * 2010-02-11 2014-01-21 Hutchison Medipharma Ltd 三氮唑並吡啶和三氮唑並吡嗪化合物及其組合物和應用
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
EA201690998A1 (ru) 2010-05-17 2017-01-30 Инкозен Терапьютикс Пвт. Лтд. НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
CN102503959B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种稠三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN102516263B (zh) * 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
EA026412B1 (ru) 2012-03-30 2017-04-28 Ризен Фармасьютикалз Са НОВЫЕ СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ c-MET ПРОТЕИНКИНАЗ
WO2013151913A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN104109166B (zh) * 2013-04-17 2017-06-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
WO2015046653A1 (ko) * 2013-09-30 2015-04-02 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
JP2018123059A (ja) * 2015-06-10 2018-08-09 石原産業株式会社 １−シクロプロピルエチルアミン又はその塩の製造方法
KR102665765B1 (ko) 2015-07-20 2024-05-10 젠자임 코포레이션 콜로니 자극 인자-1 수용체(csf-1r) 저해제
US10301325B2 (en) 2015-09-24 2019-05-28 Shanghai Haiju Biological Technology Co., Ltd. Quinoline derivative, and pharmaceutical composition, preparation method and use thereof
ES2877799T3 (es) * 2015-12-31 2021-11-17 Shanghai Pharmaceuticals Holding Co Ltd Sal de derivado de quinolina, formas polimórficas de la misma, métodos de preparación de la misma, composición y aplicaciones
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
IL263429B (en) 2016-06-20 2022-08-01 Novartis Ag Crystalline forms of triazolopyrimidine compound
KR20180092096A (ko) * 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
CN108276418A (zh) * 2018-03-20 2018-07-13 北京凯恩梅格医药科技有限公司 化合物、含有该化合物的药用组合物及其用途
EP3893872B1 (en) * 2018-12-14 2024-07-17 Beta Pharma, Inc. Organophosphorus-substituted compounds as c-met inhibitors and therapeutic uses thereof
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
WO2025098425A1 (zh) * 2023-11-09 2025-05-15 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
TR199900048T2 (xx) 1996-07-13 1999-04-21 Glaxo Group Limited Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
SK3812002A3 (en) * 1999-09-17 2003-09-11 Abbott Gmbh & Co Kg Pyrazolopyrimidines as therapeutic agents
WO2005004607A1 (en) * 2003-07-02 2005-01-20 Sugen, Inc. Arylmethyl triazolo and imidazopyrazines as c-met inhibitors
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
US9697529B2 (en) 2012-03-13 2017-07-04 American Express Travel Related Services Company, Inc. Systems and methods for tailoring marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
CA2651363C (en) 2011-07-12
US7732604B2 (en) 2010-06-08
AU2007251283A1 (en) 2007-11-22
KR101099161B1 (ko) 2011-12-27
GT200700039A (es) 2008-06-02
ECSP088871A (es) 2008-12-30
TWI346115B (en) 2011-08-01
MA30411B1 (fr) 2009-05-04
BRPI0711809A2 (pt) 2011-12-06
NO20085060L (no) 2008-12-03
CR10383A (es) 2008-11-11
ES2376913T3 (es) 2012-03-20
AR060994A1 (es) 2008-07-30
EP2018383B1 (en) 2011-11-09
UY30334A1 (es) 2008-01-02
ATE532785T1 (de) 2011-11-15
NL2000613C2 (nl) 2007-11-20
JP4377962B2 (ja) 2009-12-02
JP2009536636A (ja) 2009-10-15
MX2008014399A (es) 2008-11-27
TW200804384A (en) 2008-01-16
EA200870423A1 (ru) 2009-04-28
KR20090006187A (ko) 2009-01-14
WO2007132308A1 (en) 2007-11-22
US20070265272A1 (en) 2007-11-15
CN101443331A (zh) 2009-05-27
US20100105656A1 (en) 2010-04-29
GEP20115174B (en) 2011-03-10
ZA200809020B (en) 2009-12-30
NZ572361A (en) 2012-02-24
HN2007015177A (es) 2010-06-09
TNSN08445A1 (fr) 2010-04-14
AP2008004674A0 (en) 2008-12-31
PE20080067A1 (es) 2008-03-10
EA016204B1 (ru) 2012-03-30
CA2651363A1 (en) 2007-11-22
IL194813A0 (en) 2009-08-03
EP2018383A1 (en) 2009-01-28
RS20080533A (sr) 2009-09-08

Similar Documents

Publication Publication Date Title
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
MEP43308A (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
BRPI0407811A (pt) composto derivados de pirazolopiridina, processo para a preparação dos mesmos, composição farmacêutica e respectivos uso
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
EA200970156A1 (ru) Пиридизиноновые производные
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
HRP20050933A2 (en) Organic compounds
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0609719B8 (pt) derivados de acetilenil-pirazol-pirimidina como antagonistas de mgbur2
TW200720266A (en) Benzodioxane and benzodioxolan derivatives and uses thereof
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
CY1112401T1 (el) Παραγωγα πυριδαζινης
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
EP2613782A4 (en) INDAZONE DERIVATIVES AS ERK HEMMER
EA200870282A1 (ru) Производные амина
UY30407A1 (es) Derivados de [2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-8-il]-fenil sulfonatos sustituidos, composiciones farmacéuticas y aplicaciones.
ME00590A (en) N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
TW200700391A (en) Pyridine-2-carboxamide derivatives as mglur5 antagonists
WO2009055629A3 (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.